Associated Papers
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Cuevas-Navarro A et al.
Science Advances, 2023
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.
Su W et al.
Molecular Cell, 2022
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Poddutoori R et al.
Journal of Medicinal Chemistry, 2022
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Monaco KA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.
Tran TH et al.
Nature Communications, 2021
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X et al.
Molecular Oncology, 2020
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.
Gao Y et al.
Cancer Discovery, 2018
MEK drives BRAF activation through allosteric control of KSR proteins.
Lavoie H et al.
Nature, 2018
Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A et al.
Molecular Carcinogenesis, 2017
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z et al.
Molecular Cancer Therapeutics, 2015
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Yao Z et al.
Cancer Cell, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB et al.
Cancer Cell, 2015
U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T et al.
Archives of Toxicology, 2014
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
Hatzivassiliou G et al.
Nature, 2013
Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation.
Kilili GK et al.
The Journal of Biological Chemistry, 2010
Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization.
Yasuda S et al.
The Journal of Biological Chemistry, 2009
Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos.
Pham CD et al.
Oncogene, 1999
Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites. A dominant inhibitory role of serine 25 phosphorylation on Mos protein kinase.
Yang Y et al.
The Journal of Biological Chemistry, 1998
Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
Bosch E et al.
Oncogene, 1997
Negative regulation of Raf activity by binding of 14-3-3 to the amino terminus of Raf in vivo.
Rommel C et al.
Mechanisms of Development, 1997
Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase.
Yan M et al.
The Journal of Biological Chemistry, 1994